Treatment complications after sequential combination chemotherapy and radiotherapy with or without surgery in previously untreated squamous cell carcinoma of the head and neck.
One hundred consecutive patients with previously untreated advanced squamous cell carcinoma of the head and neck were treated with induction combination chemotherapy followed by definitive surgery and/or radiotherapy, and were evaluated for radiotherapy related toxicity. The induction regimen consisted of cisplatin, bleomycin and methotrexate/leucovorin. Acute toxicity consisted predominantly of mucositis and weight loss, and was mild or moderate by degree in 94% of patients. Six percent of patients experienced severe or life threatening acute toxicities. Two acute toxic deaths were noted in this series, one from a combination of mucositis, weight loss and infection and one from hypoglycemia of unknown origin. Thirty-five percent of patients had radiation treatment interrupted briefly because of acute toxicity. Toxicity was greatest in patients who were nonresponders to induction chemotherapy and such may have been related to the continued presence of advanced tumor. Radiotherapy dose, surgical intervention and age did not have an impact on the presence or degree of acute toxicity. Late toxicities included: hypothyroidism in 32% of patients tested: osteoradionecrosis in 5% of patients, associated primarily with a composite resection (4 of 5 cases); and soft tissue ulcerations in 3%. Taken together, these data indicate that induction combination chemotherapy did not significantly increase the toxicity of subsequent radiotherapy with or without surgery.
M R
MR
Posner
R R
RR
Weichselbaum
T J
TJ
Fitzgerald
J R
JR
Clark
C
C
Rose
R L
RL
Fabian
C M
CM
Norris
D
D
Miller
S A
SA
Tuttle
T J
TJ
Ervin
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects; D001761:Bleomycin / Q000009:adverse effects; D001835:Body Weight / Q000187:drug effects; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy / Q000628:therapy*; D002945:Cisplatin / Q000009:adverse effects; D003131:Combined Modality Therapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000473:pathology / Q000532:radiotherapy / Q000628:therapy*; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced; D002955:Leucovorin / Q000009:adverse effects; D008297:Male; D008727:Methotrexate / Q000009:adverse effects; D009092:Mucous Membrane / Q000187:drug effects; D010025:Osteoradionecrosis / Q000209:etiology; D011014:Pneumonia / Q000209:etiology; D011878:Radiotherapy / Q000009:adverse effects; D013997:Time Factors; D014456:Ulcer / Q000209:etiology
D001761:Bleomycin; D002945:Cisplatin; D002955:Leucovorin; D008727:Methotrexate